New recommendations prioritise multiparametric MRI, safer transperineal biopsy, and earlier escalation for high-risk prostate-specific antigen relapse.
Doctors began testing PSA levels in the 1980s to monitor diagnosed cancers. By the early 1990s, researchers promoted it for ...
A newly developed long-term prediction model demonstrated greater accuracy in estimating prostate cancer–specific mortality compared with existing risk assessment tools. Unlike traditional ...
News-Medical.Net on MSN
PSA-based tool improves decision making for prostate cancer screening and treatment
Prostate cancer is the second-leading cause of cancer death in American men. About 1 in 8 men will be diagnosed with prostate ...
Investigators evaluated the benefit of leuprorelin immediately after radical prostatectomy for prostate cancer in patients ...
Can PSA derivatives reduce unnecessary prostate MRI after negative biopsy? Learn how simple markers may guide imaging ...
Epigenomic profiling of circulating chromatin for early detection and monitoring of neuroendocrine prostate cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium.
A prostate-specific antigen (PSA) test is a blood test that measures a protein released in the blood by prostate cells. Both normal and cancerous prostate cells release the protein. Most of the time, ...
To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results